STRS Ohio’s Zevra Therapeutics ZVRA Stock Holding History

STRS Ohio’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$452K	Buy	+31,500	New	+$350K	﹤0.01%	1201
2025 Q2	–	Sell	-16,700	Closed	-$125K	–	2317
2025 Q1	$125K	Sell	16,700 -16,000	-49%	-$127K	﹤0.01%	1620
2024 Q4	$273K	Sell	32,700 -1,700	-5%	-$14.5K	﹤0.01%	1407
2024 Q3	$239K	Hold	34,400	–	–	﹤0.01%	1516
2024 Q2	$169K	Buy	34,400 +3,500	+11%	+$16.6K	﹤0.01%	1599
2024 Q1	$179K	Buy	30,900 +11,500	+59%	+$70.7K	﹤0.01%	1586
2023 Q4	$127K	Buy	19,400 +11,700	+152%	+$54.7K	﹤0.01%	1653
2023 Q3	$37K	Buy	+7,700	New	+$38.4K	﹤0.01%	1831
2022 Q2	–	Sell	-42,500	Closed	-$213K	–	2328
2022 Q1	$213K	Hold	42,500	–	–	﹤0.01%	1693
2021 Q4	$370K	Buy	42,500 +35,900	+544%	+$320K	﹤0.01%	1564
2021 Q3	$61K	Hold	6,600	–	–	﹤0.01%	2038
2021 Q2	$84K	Buy	+6,600	New	+$70.9K	﹤0.01%	2014

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

STRS Ohio's ZVRA Position: Q2 2026 in Review

STRS Ohio opened a new position in Zevra Therapeutics (ZVRA) in Q2 2026: 31,500 shares worth $452K. The stake represents ﹤0.01% of the portfolio and ranks #1201 among its holdings. This is a return to the name: STRS Ohio previously reported a position in ZVRA as recently as Q1 2025.

STRS Ohio first reported a position in ZVRA in Q2 2021 and has held it in 12 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

STRS Ohio held 31,500 shares of Zevra Therapeutics worth $452K as of Q2 2026.
Zevra Therapeutics was a new STRS Ohio position in Q2 2026.
Zevra Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q2 2026, its #1201 holding.
STRS Ohio first reported a position in Zevra Therapeutics in Q2 2021 and has held it in 12 quarters since.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on STRS Ohio's 13F filing for Q2 2026, filed 30 Jul 2026.